Choc septique réfractaire à la noradrénaline

Rhodes, 2017, Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016, Intensive Care Med, 43, 304, 10.1007/s00134-017-4683-6 Singer, 2016, The third international consensus definitions for sepsis and septic shock (Sepsis-3), JAMA, 315, 801, 10.1001/jama.2016.0287 Monti, 2015, Rescue therapy with polymyxin B hemoperfusion in high-dose vasopressor therapy refractory septic shock, Minerva Anestesiol, 81, 516 Svoboda, 2012, Terlipressin in the treatment of late phase catecholamine-resistant septic shock, Hepatogastroenterology, 59, 1043 Katsaragakis, 2006, Refractory septic shock: efficacy and safety of very high doses of norepinephrine, Methods Find Exp Clin Pharmacol, 28, 307, 10.1358/mf.2006.28.5.990203 O’Brien, 2002, Terlipressin for norepinephrine-resistant septic shock, Lancet Lond Engl, 359, 1209, 10.1016/S0140-6736(02)08225-9 Leone, 2004, Terlipressin in catecholamine-resistant septic shock patients, Shock Augusta Ga, 22, 314, 10.1097/01.shk.0000136097.42048.bd Martin, 2015, Norepinephrine: not too much, too long, Shock Augusta Ga, 44, 305, 10.1097/SHK.0000000000000426 Auchet, 2017, Outcome of patients with septic shock and high-dose vasopressor therapy, Ann Intensive Care, 7, 43, 10.1186/s13613-017-0261-x Yamamura, 2018, Effect of norepinephrine dosage on mortality in patients with septic shock, J Intensive Care, 6, 12, 10.1186/s40560-018-0280-1 Landry, 1997, Vasopressin deficiency contributes to the vasodilation of septic shock, Circulation, 95, 1122, 10.1161/01.CIR.95.5.1122 Sharshar, 2003, Circulating vasopressin levels in septic shock, Crit Care Med, 31, 1752, 10.1097/01.CCM.0000063046.82359.4A Lin, 2005, Low plasma vasopressin/norepinephrine ratio predicts septic shock, Am J Emerg Med, 23, 718, 10.1016/j.ajem.2005.02.055 Russell, 2008, Vasopressin versus norepinephrine infusion in patients with septic shock, N Engl J Med, 358, 877, 10.1056/NEJMoa067373 Russell, 2017, The septic shock 3.0 definition and trials: a vasopressin and septic shock trial experience, Crit Care Med, 45, 940, 10.1097/CCM.0000000000002323 Gordon, 2010, The effects of vasopressin on acute kidney injury in septic shock, Intensive Care Med, 36, 83, 10.1007/s00134-009-1687-x Gordon, 2016, Effect of early vasopressin vs. norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial, JAMA, 316, 509, 10.1001/jama.2016.10485 McIntyre, 2018, Association of vasopressin plus catecholamine vasopressors vs. catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis, JAMA, 319, 1889, 10.1001/jama.2018.4528 Leone, 2006, Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions, Crit Care Med, 34, 1126, 10.1097/01.CCM.0000206466.56669.BE Duclos, 2019, Preliminary results of synergy between norepinephrine and terlipressin during septic shock, Intensive Care Med, 10.1007/s00134-018-05514-9 Corrêa, 2015, Angiotensin II in septic shock, Crit Care Lond Engl, 19, 98, 10.1186/s13054-015-0802-3 du Cheyron, 2003, Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock-induced acute renal failure, Intensive Care Med, 29, 1703, 10.1007/s00134-003-1986-6 Mederle, 2013, The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension, Crit Care Lond Engl, 17, R130, 10.1186/cc12809 Bucher, 2001, Downregulation of angiotensin II type 1 receptors during sepsis, Hypertension, 38, 177, 10.1161/01.HYP.38.2.177 Wan, 2009, Angiotensin II in experimental hyperdynamic sepsis, Crit Care Lond Engl, 13, R190, 10.1186/cc8185 Antonucci, 2017, Angiotensin II in refractory septic shock, Shock Augusta Ga, 47, 560, 10.1097/SHK.0000000000000807 Wray, 1995, Severe septic shock unresponsive to noradrenaline, Lancet Lond Engl, 346, 1604, 10.1016/S0140-6736(95)91933-3 Thomas, 1991, Administration of angiotensin II in refractory septic shock, Crit Care Med, 19, 1084, 10.1097/00003246-199108000-00020 Chawla, 2014, Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study, Crit Care Lond Engl, 18, 534, 10.1186/s13054-014-0534-9 Khanna, 2017, Angiotensin II for the treatment of vasodilatory shock, N Engl J Med, 377, 419, 10.1056/NEJMoa1704154 Tumlin, 2018, Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II, Crit Care Med, 46, 949, 10.1097/CCM.0000000000003092 Groeneveld, 1999, Circulating endothelin and nitrate-nitrite relate to hemodynamic and metabolic variables in human septic shock, Shock Augusta Ga, 11, 160, 10.1097/00024382-199903000-00002 Brealey, 2002, Association between mitochondrial dysfunction and severity and outcome of septic shock, Lancet Lond Engl, 360, 219, 10.1016/S0140-6736(02)09459-X Landín, 1994, Inhibition of nitric oxide synthesis improves the vasoconstrictive effect of noradrenaline in sepsis, Chest, 106, 250, 10.1378/chest.106.1.250 Pastor, 1995, Nitric oxide causes hyporeactivity to phenylephrine in isolated perfused livers from endotoxin-treated rats, Am J Physiol, 268, G177 Broccard, 2000, Tissue oxygenation and hemodynamic response to NO synthase inhibition in septic shock, Shock Augusta Ga, 14, 35, 10.1097/00024382-200014010-00007 Bakker, 2004, Crit Care Med, 32, 1, 10.1097/01.CCM.0000105118.66983.19 Watson, 2004, Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study No. 144-002), Crit Care Med, 32, 13, 10.1097/01.CCM.0000104209.07273.FC Grover, 1999, An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group, Crit Care Med, 27, 913, 10.1097/00003246-199905000-00025 López, 2004, Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock, Crit Care Med, 32, 21, 10.1097/01.CCM.0000105581.01815.C6 Lamontagne, 2016, Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial, Intensive Care Med, 42, 542, 10.1007/s00134-016-4237-3 Rosselet, 1998, Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock, Am J Respir Crit Care Med, 157, 162, 10.1164/ajrccm.157.1.9701017 Kadoi, 2004, Selective inducible nitric oxide inhibition can restore hemodynamics, but does not improve neurological dysfunction in experimentally-induced septic shock in rats, Anesth Analg, 99, 212, 10.1213/01.ANE.0000118111.94913.22 Wray, 1998, Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin, Shock Augusta Ga, 9, 329, 10.1097/00024382-199805000-00003 Rosengarten, 2009, Effects of inducible nitric oxide synthase inhibition or norepinephrine on the neurovascular coupling in an endotoxic rat shock model, Crit Care Lond Engl, 13, R139, 10.1186/cc8020 Keaney, 1994, Methylene blue reverses endotoxin-induced hypotension, Circ Res, 74, 1121, 10.1161/01.RES.74.6.1121 Mayer, 1993, Inhibition of nitric oxide synthesis by methylene blue, Biochem Pharmacol, 45, 367, 10.1016/0006-2952(93)90072-5 Kirov, 2001, Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study, Crit Care Med, 29, 1860, 10.1097/00003246-200110000-00002 Memis, 2002, The influence of methylene blue infusion on cytokine levels during severe sepsis, Anaesth Intensive Care, 30, 755, 10.1177/0310057X0203000606 Vieillard-Baron, 2008, Actual incidence of global left ventricular hypokinesia in adult septic shock, Crit Care Med, 36, 1701, 10.1097/CCM.0b013e318174db05 Parker, 1984, Profound but reversible myocardial depression in patients with septic shock, Ann Intern Med, 100, 483, 10.7326/0003-4819-100-4-483 Jardin, 1990, Sepsis-related cardiogenic shock, Crit Care Med, 18, 1055, 10.1097/00003246-199010000-00001 MacLaren, 2011, Central extracorporeal membrane oxygenation for refractory pediatric septic shock, Pediatr Crit Care Med, 12, 133, 10.1097/PCC.0b013e3181e2a4a1 Davis, 2017, American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock, Crit Care Med, 45, 1061, 10.1097/CCM.0000000000002425 Bréchot, 2013, Venoarterial extracorporeal membrane oxygenation support for refractory cardiovascular dysfunction during severe bacterial septic shock, Crit Care Med, 41, 1616, 10.1097/CCM.0b013e31828a2370 Park, 2015, Extracorporeal membrane oxygenation for refractory septic shock in adults, Eur J Cardiothorac Surg, 47, e68, 10.1093/ejcts/ezu462 Cheng, 2016, Predictors of survival in adults undergoing extracorporeal membrane oxygenation with severe infections, J Thorac Cardiovasc Surg, 152, 10.1016/j.jtcvs.2016.08.038 Choudhury, 2017, A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock, Liver Int, 37, 552, 10.1111/liv.13252